Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
385.65
+5.87 (1.55%)
At close: Sep 18, 2026, 4:00 PM EDT
385.73
+0.08 (0.02%)
After-hours: Sep 18, 2026, 7:59 PM EDT
Amgen Market Cap
Amgen has a market cap or net worth of $208.49 billion as of September 18, 2026. Its market cap has increased by 40.98% in one year.
Market Cap
208.49B
Enterprise Value
251.81B
1-Year Change
40.98%
Ranking
Category
Stock Price
$385.65
ChartMarket Cap Chart
Since December 1, 1998, Amgen's market cap has increased from $19.50B to $208.49B, an increase of 969.06%. That is a compound annual growth rate of 8.89%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 18, 2026 | 208.49B | 18.29% |
| Dec 31, 2025 | 176.25B | 25.80% |
| Dec 31, 2024 | 140.10B | -9.11% |
| Dec 29, 2023 | 154.14B | 9.99% |
| Dec 30, 2022 | 140.14B | 10.59% |
| Dec 31, 2021 | 126.72B | -5.33% |
| Dec 31, 2020 | 133.85B | -6.55% |
| Dec 31, 2019 | 143.24B | 15.47% |
| Dec 31, 2018 | 124.05B | -1.73% |
| Dec 29, 2017 | 126.24B | 16.06% |
| Dec 30, 2016 | 108.77B | -11.17% |
| Dec 31, 2015 | 122.45B | 1.06% |
| Dec 31, 2014 | 121.17B | 40.84% |
| Dec 31, 2013 | 86.03B | 30.06% |
| Dec 31, 2012 | 66.15B | 17.52% |
| Dec 30, 2011 | 56.28B | 8.51% |
| Dec 31, 2010 | 51.87B | -9.41% |
| Dec 31, 2009 | 57.26B | -6.42% |
| Dec 31, 2008 | 61.19B | 21.14% |
| Dec 31, 2007 | 50.51B | -36.61% |
| Dec 29, 2006 | 79.68B | -18.14% |
| Dec 30, 2005 | 97.34B | 19.46% |
| Dec 31, 2004 | 81.48B | 2.22% |
| Dec 31, 2003 | 79.71B | 28.11% |
| Dec 31, 2002 | 62.22B | 5.44% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 650.65B |
| AbbVie | 466.45B |
| Merck & Co. | 362.35B |
| Novartis AG | 265.70B |
| AstraZeneca | 259.31B |
| Novo Nordisk | 191.02B |
| Gilead Sciences | 186.13B |
| Pfizer | 157.65B |